Latest Breaking News On - Design therapeutics - Page 1 : vimarsana.com

Stuttering Market to Register Stunning Growth at a CAGR of 13.4% by 2034

/PRNewswire/ -- DelveInsight's Stuttering Market Insights report includes a comprehensive understanding of current treatment practices, stuttering emerging...

DelveInsight Business Research, LLP: Stuttering Market to Register Stunning Growth at a CAGR of 13.4% by 2034

The anticipated introduction of new therapeutic options could lead to an expansion of the market for stuttering treatment during the forecast period. This growth may be fueled by factors such

HBM Healthcare Investments : Invitation to Ordinary Shareholders' Meeting of 17.06.2024

HBM Healthcare Investments Ltd Bundesplatz 1, 6300 Zug Invitation to the 23rd Ordinary Shareholders' Meeting Monday,...

Larimar stock rallies 24% on FDA removal of partial clinical hold (NASDAQ:LRMR)

Design Therapeutics (NASDAQ:DSGN) Rating Increased to Overweight at Piper Sandler

DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in Stock

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The shares were bought at an average price of $3.74 per share, with a total value of $66,605.66. Following the completion of the acquisition, the director now directly owns […]

Independent Director of Design Therapeutics Picks Up 88% More Stock

Whilst it may not be a huge deal, we thought it was good to see that the Design Therapeutics, Inc. ( NASDAQ:DSGN...

John P. Schmid Acquires 9,156 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) Stock

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid acquired 9,156 shares of Design Therapeutics stock in a transaction on Friday, March 22nd. The stock was acquired at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the purchase, the director now owns 9,156 […]

Insider Buying: Design Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases 9,156 Shares of Stock

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid bought 9,156 shares of the company’s stock in a transaction on Friday, March 22nd. The stock was purchased at an average cost of $3.62 per share, with a total value of $33,144.72. Following the completion of the transaction, the director now owns 9,156 […]